NephroGenex, Inc (OTCMKTS:NRXGQ – Get Free Report) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.00. NephroGenex shares last traded at $0.00, with a volume of 2,000 shares traded.
NephroGenex Price Performance
About NephroGenex
NephroGenex, Inc is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe.
Further Reading
- Five stocks we like better than NephroGenex
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- What is a Death Cross in Stocks?
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for NephroGenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NephroGenex and related companies with MarketBeat.com's FREE daily email newsletter.
